Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
Given these compelling results, Creative Medical Technology plans to advance the development of AlloStem (CELZ-201) for the treatment of late-stage Type 2 Diabetes and explore other potential ...
Creative Medical Technology Holdings, Inc.: Creative Medical Technology Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced ...
Creative Medical reports progress in Type 2 Diabetes treatment
Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology firm specializing in regenerative medicine with a market capitalization of approximately $7 million, has revealed promising one-year follow-up ...
ScienceAlert2h
Identifying Chemicals in Our Environment Could Help Medicines Work Better
Your genes play a major role in determining your height, hair and eye color, and skin tone, but they don't tell the entire ...